Brian Buntz - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Brian Buntz's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Brian Buntz
Verified
Pharma Editor, Drug Discovery & Development
Berkeley
Beats
Sociology , Labor Unions, Global Health , Health Equity, Social Movements , Breaking News, Labor Politics, Politics , Infectious Diseases
religion, entertainment, sports
Content
By Brian Buntz Verified| R&D World Verified Thermo Fisher Scientific has rolled out three floor‑model centrifuge families—Cryofuge, BIOS and LYNX—that use a natural refrigerant with a global‑warming potential (GWP) of 1, roughly 1,400 times lower than the hydrofluorocarbon (HFC) blends found in the company’s previous Sorvall line.
OpenAI releases o3, a model that tops 99% of human competitors on IOI 2024 and Codeforces benchmarks - Research & Development World
By Brian Buntz Verified| R&D World Verified OpenAI has just announced the gradual release of o3 and o4‑mini, models that it says represent a notable step forward in AI reasoning for STEM fields. The models combine deeper “thinking” capabilities (test‑time compute) with full tool access.
By Brian Buntz Verified| R&D World Verified Thermo Fisher Scientific has rolled out three floor‑model centrifuge families—Cryofuge, BIOS and LYNX—that use a natural refrigerant with a global‑warming potential (GWP) of 1, roughly 1,400 times lower than the hydrofluorocarbon (HFC) blends found in the company’s previous Sorvall line.
Company Info
Drug Discovery & Development
Drug Discovery and Development is a prominent digital publication that provides insights and updates in the fields of pharmaceutical research, drug formulation, and clinical trials. It serves as a valuable resource for professionals in the pharma and biotech industries, focusing on trends such as AI applications and research in neurological diseases. The platform offers industry reporting, educational content, and trend monitoring. Its editorial content includes news articles on clinical trials and regulatory approvals, special reports on topics like biomarker development, and resource libraries that likely contain industry whitepapers and conference summaries. The publication targets researchers, regulatory affairs specialists, and business development executives, providing them with essential information to stay informed about the latest developments in drug discovery and development processes.
'+1 973-920-7033